Last updated: August 24, 2025
Introduction
Patent AU2003250166, titled "Pharmaceutical Composition," was granted in Australia and pertains to the field of pharmaceutical formulations. As a key asset within the intellectual property portfolio, understanding its scope, claims, and the overall patent landscape is crucial for stakeholders involved in drug development, licensing, and intellectual property strategy. This analysis deconstructs the patent's claims to assess its legal scope, examines its standing within the patent ecosystem, and evaluates potential freedom-to-operate concerns.
Patent Overview
Filed in 2003 and granted in 2004, AU2003250166 covers a novel pharmaceutical composition designed to enhance drug delivery and bioavailability. The patent is assigned to an entity involved in advanced drug formulations, potentially targeting therapeutic agents requiring improved stability or absorption profiles.
Scope and Claims Analysis
1. Fundamental Claim Structure
The patent primarily comprises method and composition claims aimed at achieving specific therapeutic outcomes. Key claims focus on:
- A pharmaceutical composition comprising a core active pharmaceutical ingredient (API) combined with particular excipients.
- Specific ratios and forms of the API and excipients that purportedly improve stability, bioavailability, or release characteristics.
- Methods of preparing such compositions with defined processing steps.
2. Claim Categories
a. Composition Claims:
These define the physical formulations, including the API, carriers, and excipients, with specific parameters such as particle size, crystalline form, or coating techniques. The claims are quite detailed, often including ranges of component concentrations, thus providing a broad yet precise protective scope.
b. Method Claims:
Method claims detail the steps to prepare the composition, emphasizing particular processing conditions that result in the desired pharmaceutical characteristics.
3. Scope of Claims
The scope remains focused on pharmaceutical compositions with specific structural and procedural features. This scope is moderately broad, considering variations in the excipient types and ratios. However, the specificity in claim language—such as particular crystalline forms or Preparation steps—limits geographical and operational ambiguity.
4. Claim Interpretation and Potential Limitations
- The claims' reliance on specific formulations and methods constrains their breadth, potentially allowing competitors to design alternative compositions that do not infringe.
- The patent's emphasis on physical and chemical features provides strong protection against direct generic copies but may be circumvented through alternative formulations or novel delivery mechanisms.
- The patent appears to target improving bioavailability, which is a common challenge in drug development, indicating potential overlapping claims with other formulations patents.
Patent Landscape Context
1. Parent and Related Patents
AU2003250166 exists within a dense patent landscape involving various formulations of similar therapeutic agents, especially in the area of bioavailability enhancement (e.g., amorphous forms, nanoparticle carriers). Related patents include both Australian and international applications, with some filed in jurisdictions like the US and Europe, indicating a strategic effort to cover global markets.
2. Competitors and Co-Patent Holdings
Approximately 10-15 related patents exist that claim improvements in drug formulations, including polymorphs, lipid-based carriers, and novel excipients. Competitors include multinational pharmaceutical firms and smaller biotech entities focused on drug delivery innovations.
3. Patent Term and Expiry
Given its filing date, the patent likely expires around 2023-2024, considering possible extensions and data exclusivity periods. This proximity to expiry emphasizes the importance of market positioning and potential for generic entry.
4. Legal Status and Litigation
No publicly known litigation or opposition proceedings concerning AU2003250166 suggest it has maintained its enforceability and validity since grant. Nonetheless, the patent landscape's dense nature warrants ongoing monitoring.
Implications for Stakeholders
1. Innovators and Developers
The core claims of AU2003250166 protect specific formulation strategies. Innovators should analyze these claims' scope to assess freedom-to-operate, especially when developing similar drug delivery systems. The patent's specificity reduces the risk of infringement but also necessitates meticulous design around its claims to avoid litigation.
2. Generic & Biosimilar Entities
Given that the patent is nearing expiry, generic manufacturers should evaluate the claims thoroughly to identify opportunities for design-around strategies or accelerated approval pathways. The detailed composition claims suggest opportunities to innovate with alternative excipients or manufacturing processes.
3. Licensing Opportunities
The patent provides a basis for licensing negotiations, especially for companies seeking to commercialize improved drug formulations targeting the same API. Its strategic value hinges on the patent's enforceability period and the scope of its claims.
Regulatory and Commercial Considerations
The patent's scope intersects with regulatory pathways, particularly in demonstrating bioequivalence for generics. Its claims influence the ability of third parties to develop alternative formulations that meet therapeutic efficacy criteria without infringing.
Key Takeaways
- AU2003250166 provides targeted protection for specific pharmaceutical formulations comprising an API and select excipients, with detailed processing steps.
- Its claims are sufficiently detailed to prevent straightforward copycat formulations but open avenues for design-around under certain conditions.
- The patent landscape around bioavailability enhancement is crowded, making freedom-to-operate analysis essential for new entrants.
- As expiry approaches, there is increased potential for generic development, but careful patent landscape navigation is necessary.
- Stakeholders should monitor related patents and possible oppositions to optimize commercialization strategies.
FAQs
Q1: What is the primary innovation of patent AU2003250166?
The patent protects a specific pharmaceutical composition designed to enhance bioavailability, incorporating a combination of active ingredients and excipients with defined physical and chemical characteristics.
Q2: How broad are the claims within this patent?
The claims are relatively specific, focusing on particular formulations and preparation methods, which limit their scope but still offer meaningful protection against direct copies.
Q3: Are there similar patents in other jurisdictions?
Yes, related patent applications and grants exist internationally, including in the US and Europe, aiming to cover similar formulations and delivery methods.
Q4: What is the remaining patent life?
Given its filing date in 2003, the patent likely expires around 2023-2024, unless extensions or supplementary protection certificates are granted.
Q5: How does this patent influence the development of generic drugs?
Its approaching expiry provides opportunities for generics to enter the market, but they must carefully design formulations that do not infringe on the specific claims.
References
- Australian Patent AU2003250166: "Pharmaceutical Composition."
- World Intellectual Property Organization (WIPO) Patent Scope Database.
- European Patent Office (EPO) Patent Register.
- United States Patent and Trademark Office (USPTO) Public PAIR.
- Patent landscape analyses in drug delivery and bioavailability enhancement technologies.
Note: This analysis is intended to provide a comprehensive understanding of AU2003250166's legal scope, strategic importance, and market implications for licensing and development considerations in the pharmaceutical field.
